Introduction
Cohort studies have established the prognostic value of peripheral blood CD4 counts.IA They are routinely used to assess HIV-related immunosuppression, to decide when to start antimicrobial prophylaxis and antiretroviral therapy, and extensively in clinical trials. However, circulating lymphocytes represent a tiny fraction of the total body lymphoid pool. The majority are in the lymph nodes which are the main sites of HIV replication early in HIV infection.5 A functional assessment of CD4 lymphocytes, though not currently routinely available, might provide more information.
Interpretation of the CD4 count requires an understanding of its biological variability and that due to the method of measurement.67 The analysis of CD4 counts in HIV-negative populations may help to define this variability.
Heterosexuals, who constitute an increasing proportion of HIV infected patients, have not been extensively studied. Increased percentages of CD4 cells (CD4%) and absolute CD4 counts in HIV seronegative women compared with heterosexual men have been reported, but these studies have not controlled for potential confounders such as smoking and diurnal variation.8"-3
We have measured lymphocyte subsets in HIV seronegative women and heterosexual men to identify any difference by gender and any effect of the menstrual cycle, oral contraceptive use and cigarette smoking. The study was designed to minimise the effect of procedural and diurnal variability and to collect data on potential confounders. We have compared the results with those obtained in an earlier, small study of homosexual men. Women who had started menstruation within 3 days of recruitment were then analysed separately. tTreatment last 3 months: antibiotics 49; psychotropics 9; NSAIDs/other analgesics 8.
Methods
::Current STDs: NSU 12; Chlamydia 5; HSV 2; PID 2; UTI 3 (Candida, BV, warts excluded). §Illnesses last 3 months: viral/bacterial infection 43 (most upper respiratory tract). An effect of the menstrual cycle was sought, after excluding women using hormonal contraception, those with erratic cycles and the post-menopausal (n = 80). Pre-ovulatory women (n = 56) had higher CD4% than post-ovulatory women (n = 59, p = 0.047). Further analysis showed that women who were menstruating (n = 11) had higher CD4% than others (n = 104, p = 0.038), but those within 2 days of ovulating did not differ significantly (data not shown). There were no significant differences in absolute CD4 counts.
Gender, smoking and recent illness showed significant associations with CD4 count after adjusting for other variables in a multiple linear regression model, suggesting that they act independently. The adjusted differences in mean CD4 count indicate the strongest association was with smoking (142/mm3 higher in smokers; p = 0.0001), followed by gender (108/mm3 higher in females; p = 0.002), and recent illness (80/mm3 higher if recent illness, p = 0.04). When oestrogen oral contraceptive use was included in a model fitted for women only, the difference in mean CD4 count was 66/mm3 (higher in non-pill users; p = 0.13). There were no statistically significant interaction effects observed. The R-square value for the multiple linear regression model was 0 12, indicating that these variables can only explain a small proportion of all inter-individual variability in CD4 counts.
Similar analyses were conducted for CD8 counts and CD8%, lymphocyte counts and CD4:CD8 ratio (data not shown). There were significant associations between total lymphocyte counts and CD8 counts and smoking, and between CD8 counts, CD8% and CD4:CD8 ratio and menstruation. There were no gender differences in CD8 counts, CD8%, CD4:CD8 ratio or total lymphocyte count. Table 2 shows the reference ranges calculated for male and female non-smokers and smokers for CD4% and absolute counts, CD8% and absolute counts, total lymphocyte counts and CD4:CD8 ratios.
The mean CD4 count and CD4% in the group of 45 '3 or HIV status.9 12 13 Procedural factors affect the reliability of lymphocyte subset counts. In this study all samples were kept at room temperature until the total lymphocyte count was measured by automated counter in a single laboratory, within 6 hours. In other studies the procedure was either not specified9 14 or was not uniform8 leading to only CD4% being reported.""11
Flow cytometry is more reproducible than manual fluorescence as used in other studies"" and whole blood staining eliminates prior lymphocyte separation, a potential source of cell loss.9 12-14 17 CD4-lymphocyte counts exhibit circadian variation of up to 60% with the nadir at about 11.00 am. '5 18 In this study all samples were taken between 9.30am and 12.30pm. Circannual variability in CD4% has been reported, with higher levels in April19 and October/November,'920 but no such effect was seen in the present study (data not shown). CD4% has been shown to increase with age by 1 % per decade,9-11 but no such effect was detectable in this study. As reported previously9 21 there were no racial differences in CD4 counts, although our study population was largely Caucasian. Smoking is associated with a leucocytosis, a lymphocytosis and an increase in CD4% and CD4 absolute counts.'72223 This was confirmed here and shown to be independent of gender. There was a dose-response effect of smoking, consistent with previous reports'723 and reports of reversibility of the effect in ex-smokers."722 These findings strengthen the evidence for a causal relationship.
We included only patients who were tested HIV-antibody negative. Although 29% of the heterosexuals had had unprotected intercourse in the 3 months prior to testing, the chance of any of them being in the seroconversion window period is very small, given the overall prevalence of HIV of one in 286 recruits. None had a history of other serious illness associated with CD4 lymphopaenia.2F27 No significant association was found between CD4 counts and the presence of an STD diagnosed at the time, although the number of patients was small. As expected, there was an association between other recent illness, most commonly upper respiratory tract infections, and an increase in CD4 count.
Treatment with cyclophosphamide or prednisolone has been associated with a decrease in CD4 counts,2" but in this study no association with medication was observed. Only 11 patients had a history of injecting drug misuse; however, there was a trend (p = 0.09) towards them having a lower CD4%. We found no difference in either CD4 counts or CD4% between heterosexual men and the group of homosexual men tested in 1990.
One possible explanation for the observed gender difference in CD4 counts is a sex hormone effect. Circulating lymphocytes have receptors for androgens and oestrogens,29 and these hormones also exhibit diurnal and circannual rhythimicity. '6'930 If the adult female pattern of hormones is responsible for the difference in CD4 counts, the gender difference might be expected to appear at puberty. Tollerud et al found a gender difference in 17-19 year olds, but not in 12-16 year olds. '4 In adults under 40 years or age, Ohta et al '3 found higher CD4 counts in women than in men, but no difference in those over 40. A small study3' found that hormone replacement therapy had no effect on CD4 counts in post-menopausal women. Changes in CD4 count and CD4% have been observed in pregnant women,32 who were therefore excluded from our study.
A previous small study found that the menstrual cycle and OCP use had no effect on CD4% but did not control for other variables. 33 
